Arcus Biosciences [RCUS] vs Dyne Therapeutics [DYN] Detailed Stock Comparison

Arcus Biosciences

NYSE
Loading...

Dyne Therapeutics

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 17 vital metrics comparison: Arcus Biosciences wins in 8 metrics, Dyne Therapeutics wins in 7 metrics, with 0 ties. Arcus Biosciences appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricArcus BiosciencesDyne TherapeuticsBetter
P/E Ratio (TTM)-3.67-3.90Dyne Therapeutics
Price-to-Book Ratio2.232.63Arcus Biosciences
Debt-to-Equity Ratio23.6821.19Dyne Therapeutics
PEG Ratio0.04-0.10Dyne Therapeutics
EV/EBITDA-1.36-2.98Dyne Therapeutics
Profit Margin (TTM)-113.74%0.00%Dyne Therapeutics
Operating Margin (TTM)-5.00%0.00%Dyne Therapeutics
Return on Equity-50.34%-61.32%Arcus Biosciences
Return on Assets (TTM)-18.69%-35.45%Arcus Biosciences
Free Cash Flow (TTM)$-176.00M$-294.75MArcus Biosciences
1-Year Return-35.82%-61.39%Arcus Biosciences
Price-to-Sales Ratio (TTM)4.68N/AN/A
Enterprise Value$445.08M$1.31BDyne Therapeutics
EV/Revenue Ratio1.70N/AN/A
Revenue per Share (TTM)$3$0Arcus Biosciences
Earnings per Share (Diluted)$-3.14$-3.88Arcus Biosciences
Beta (Stock Volatility)0.831.10Arcus Biosciences
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

Arcus Biosciences vs Dyne Therapeutics Stock Performance Analysis

Loading Price Chart...

Arcus Biosciences
Dyne Therapeutics
Arcus Biosciences Stock Overview | Dyne Therapeutics Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Arcus Biosciences0.17%-5.50%19.13%23.21%18.76%-23.86%
Dyne Therapeutics-0.19%-7.52%13.17%-9.06%6.39%-48.35%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Arcus Biosciences-35.82%-55.56%-47.49%-34.55%-34.55%-34.55%
Dyne Therapeutics-61.39%-3.66%-42.32%-42.32%-42.32%-42.32%

News Based Sentiment: Arcus Biosciences vs Dyne Therapeutics

Arcus Biosciences

News based Sentiment: POSITIVE

Arcus Biosciences delivered exceptional Q2 results, exceeding expectations significantly, and continues to advance its clinical programs with promising data. While insider selling and trading volatility exist, the overall narrative is positive, supported by analyst confidence and upcoming catalysts.

View Arcus Biosciences News Sentiment Analysis

Dyne Therapeutics

News based Sentiment: POSITIVE

September was a significant month for Dyne Therapeutics, marked by positive clinical data for their DM1 program, active investor engagement at key conferences, and a clear timeline for upcoming data readouts and BLA submissions. These developments strengthen the investment case and suggest the company is progressing towards potential commercialization, though risks related to trial outcomes and regulatory approval remain.

View Dyne Therapeutics News Sentiment Analysis

Performance & Financial Health Analysis: Arcus Biosciences vs Dyne Therapeutics

MetricRCUSDYN
Market Information
Market Cap i$1.23B$1.87B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i863,3702,080,960
90 Day Avg. Volume i794,1772,782,247
Last Close$11.52$13.15
52 Week Range$6.50 - $18.98$6.36 - $37.08
% from 52W High-39.30%-64.54%
All-Time High$49.10 (Nov 22, 2021)$47.45 (Aug 19, 2024)
% from All-Time High-76.54%-72.29%
Growth Metrics
Quarterly Revenue Growth3.10%N/A
Quarterly Earnings Growth3.10%N/A
Financial Health
Profit Margin (TTM) i-1.14%0.00%
Operating Margin (TTM) i-0.05%0.00%
Return on Equity (TTM) i-0.50%-0.61%
Debt to Equity (MRQ) i23.6821.19
Cash & Liquidity
Book Value per Share (MRQ)$5.16$5.00
Cash per Share (MRQ)$8.56$4.81
Operating Cash Flow (TTM) i$-339,000,000$-359,560,000
Levered Free Cash Flow (TTM) i$-113,000,000$-222,398,000
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Arcus Biosciences vs Dyne Therapeutics

MetricRCUSDYN
Price Ratios
P/E Ratio (TTM) i-3.67-3.90
Forward P/E i-2.47-4.16
PEG Ratio i0.04-0.10
Price to Sales (TTM) i4.68N/A
Price to Book (MRQ) i2.232.63
Market Capitalization
Market Capitalization i$1.23B$1.87B
Enterprise Value i$445.08M$1.31B
Enterprise Value Metrics
Enterprise to Revenue i1.70N/A
Enterprise to EBITDA i-1.36-2.98
Risk & Other Metrics
Beta i0.831.10
Book Value per Share (MRQ) i$5.16$5.00

Financial Statements Comparison: Arcus Biosciences vs Dyne Therapeutics

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)RCUSDYN
Revenue/Sales i$28.00M$0
Cost of Goods Sold iN/AN/A
Gross Profit iN/AN/A
Research & Development i$122.00M$99.24M
Operating Income (EBIT) i$-122.00M$-115.79M
EBITDA i$-108.00M$-110.26M
Pre-Tax Income i$-112.00M$-110.86M
Income Tax i$0N/A
Net Income (Profit) i$-112.00M$-110.86M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)RCUSDYN
Cash & Equivalents i$192.00M$472.26M
Total Current Assets i$1.03B$689.50M
Total Current Liabilities i$192.00M$33.88M
Long-Term Debt i$48.00M$18.22M
Total Shareholders Equity i$531.00M$668.97M
Retained Earnings i$-1.24B$-1.07B
Property, Plant & Equipment iN/A$34.19M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)RCUSDYN
Operating Cash Flow i$-128.00M$-110.37M
Capital Expenditures i$-1.00M$-981,000
Free Cash Flow i$-133.00M$-106.87M
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricRCUSDYN
Shares Short i9.83M16.04M
Short Ratio i13.275.24
Short % of Float i0.14%0.13%
Average Daily Volume (10 Day) i863,3702,080,960
Average Daily Volume (90 Day) i794,1772,782,247
Shares Outstanding i92.20M102.32M
Float Shares i59.89M122.63M
% Held by Insiders i0.35%0.00%
% Held by Institutions i0.68%0.95%

Dividend Analysis & Yield Comparison: Arcus Biosciences vs Dyne Therapeutics

MetricRCUSDYN
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A